Insulin detemir in the management of type 2 diabetes in non-Western countries: Safety and effectiveness data from the A1chieve observational study

Zilov, Alexey; Naggar, Nabil El; Shah, Siddharth; Shen, Chunduo; Haddad, Jihad

doi:10.1016/j.diabres.2013.06.003

Cited by 6 publications

(10 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although the HAT study is one of the largest, real‐world, global prospective hypoglycaemia studies with diaries conducted to date (n = 27 585), several other studies involved large numbers of participants. The Predictable Results and Experience in Diabetes through Intensification and Control to Target [PREDICTIVE] study included 7420 patients with T1D and 12 981 patients with T2D; the A1chieve study included 66 726 patients with T2D; and the JADE study included 18 589 patients with T2D …”

Section: Resultsmentioning

confidence: 99%

“…Real‐world studies of patients with T2D included global studies (GAPP2, A1chieve and SOLVE), European studies (GAPP2 UK, a self‐reported non‐severe hypoglycaemic events study in Europe, a self‐reported non‐severe hypoglycaemic events study in Germany, the PREDICTIVE and DIALOG studies, the UK Hypoglycaemia study, a single‐centre survey in Germany, the UK self‐reporting study, the PANORAMA and ICU cohort studies), Asian/South East Asian studies (Physicians' Routine Evaluation of Safety and Efficacy of NovoMix 30 Therapy [PRESENT], COMPASS, Diabetes Disease Specific Programme [DSP] China, the JADE study, a single‐centre study in India, a basal insulin dose‐timing study in Japan) and one study from North America (GAPP2 Canada).…”

Section: Resultsmentioning

confidence: 99%

“…[PREDICTIVE] study included 7420 patients with T1D and 12 981 patients with T2D; 26 the A1chieve study included 66 726 patients with T2D; 29 and the JADE study included 18 589 patients with T2D. 21 Patient selection and inclusion criteria for the HAT study were generally aligned with those of the other studies, that is, adult patients with T1D and/or T2D who were currently undergoing treatment with insulin.…”

Section: Evaluation Of the Hat Study And Comparative Real-world CLImentioning

confidence: 99%

“…21 Patient selection and inclusion criteria for the HAT study were generally aligned with those of the other studies, that is, adult patients with T1D and/or T2D who were currently undergoing treatment with insulin. 15 However, selected studies included patients less than 18 years of age (self-reported non-severe hypoglycaemic events in Europe, 3 self-reported non-severe hypoglycaemic events in Germany, 27 the A1cheive study, 29 the UK self-reporting study, 30 and self-reported insulin adherence in Brazil 22 ) or they included only patients who were at least 40 years of age (the GAPP2 6,16,31 and the PANORAMA 20 studies).…”

Section: Evaluation Of the Hat Study And Comparative Real-world CLImentioning

confidence: 99%

“…Rates of overall and mild/non-severe hypoglycaemia were similar, between 19 and 40 events PPY, in the HAT 19 and GAPP2 21 studies and in two European self-reported studies. 4,29 According to the HAT study, Northern and Eastern Europe rates of non-severe hypoglycaemia were 18.1 PPY and 23.7 PPY, respectively. Other studies, such as PREDICTIVE 27 , A1chieve 29 and SOLVE, 37 reported lower rates of 1.3 to 3.1 events PPY.…”

Section: T2d: Overall and Mild/non-severe Hypoglycaemiamentioning

confidence: 99%

See 4 more Smart Citations

Comparison of the HAT study, the largest global hypoglycaemia study to date, with similar large real‐world studies

Pedersen‐Bjergaard

Alsifri

Aronson

et al. 2018

Diabetes Obesity Metabolism

View full text Add to dashboard Cite

Aims Optimal diabetes care requires clear understanding of the incidence of hypoglycaemia in real‐world clinical practice. Current data on hypoglycaemia are generally limited to those reported from randomised controlled clinical trials. The Hypoglycaemia Assessment Tool (HAT) study, a non‐interventional real‐world study of hypoglycaemia, assessed hypoglycaemia in 27 585 individuals across 24 countries. The present study compared the incidence of hypoglycaemia from the HAT study with other similarly designed, large, real‐world studies. Materials and Methods A literature search of PubMed (1995‐2017) for population‐based studies of insulin‐treated patients with type 1 or type 2 diabetes (T1D, T2D), excluding clinical trials and reviews, identified comparable population‐based studies reporting the incidence of hypoglycaemia. Results The 24 comparative studies, including more than 24 000 participants with T1D and more than 160 000 participants with T2D, varied in design, size, inclusion criteria, definitions of hypoglycaemia and method of recording hypoglycaemia. Reported rates (events per patient‐year [PPY]) of hypoglycaemia were higher in patients with T1D than in those with T2D (overall T1D, 21.8‐73.3 and T2D, 1.3‐37.7; mild/non‐severe T1D, 29.0‐126.7 and T2D, 1.3‐41.5; severe T1D, 0.7‐5.8 and T2D, 0.0‐2.5; nocturnal T1D, 2.6‐11.3 and T2D, 0.38‐9.7) and were similar to the ranges found in the HAT study. Conclusions The HAT data on hypoglycaemia incidence were comparable with those from other real‐world studies and indicate a high incidence of hypoglycaemia among insulin‐treated patients. Differences in rates among studies are mostly explained by differences in patient populations and study methodology. The goal of reducing hypoglycaemia should be a target for continued educational and evidence‐based pharmacological interventions.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Evaluation Of the Hat Study And Comparative Real-world CLImentioning

confidence: 99%

Section: Evaluation Of the Hat Study And Comparative Real-world CLImentioning

confidence: 99%

Section: T2d: Overall and Mild/non-severe Hypoglycaemiamentioning

confidence: 99%

See 3 more Smart Citations

Comparison of the HAT study, the largest global hypoglycaemia study to date, with similar large real‐world studies

Pedersen‐Bjergaard

Alsifri

Aronson

et al. 2018

Diabetes Obesity Metabolism

View full text Add to dashboard Cite

show abstract

Análisis de costo-utilidad del uso de detemir en pacientes con diabetes tipo 2

Romero-Prada

Huérfano-Rey

Páez

et al. 2015

RGYPS

View full text Add to dashboard Cite

Objetivo: realizar un análisis de costo-utilidad para evaluar el tratamiento con las diferentes opciones de insulina en pacientes diabéticos tipo 2. Metodología: partiendo del análisis realizado previamente por Romero et al., se actualizó la información y se incluyó un análisis específico para calidad de vida. El modelo de Markov simuló pacientes tratados con insulina nph, detemir o glargina. Se consideraron los eventos de hipoglucemia más sus complicaciones. Los costos corresponden al precio máximo de regulación por dosis. Los costos de eventos son tomados de registros del sistema de información de transacciones de entidades prestadoras de salud al año 2014. Resultados: los avac con detemir se calculan en 2,604, en comparación con 2,545 con glargina y 2,533 con nph. Los análisis de sensibilidad muestran dominancia de detemir. Conclusiones: detemir es una opción favorable por su seguridad, efectividad y costo, demostrando beneficios medidos en avac sobre sus comparadores.

show abstract

Geographical clustering and socioeconomic factors associated with hypoglycemic events requiring emergency assistance in Andalusia (Spain)

Gómez-Peralta

Abreu

Benito

et al. 2021

BMJ Open Diab Res Care

View full text Add to dashboard Cite

IntroductionThe geographical distribution of hypoglycemic events requiring emergency assistance was explored in Andalusia (Spain), and potentially associated societal factors were determined.Research design and methodsThis was a database analysis of hypoglycemia requiring prehospital emergency assistance from the Public Company for Health Emergencies (Empresa Pública de Emergencias Sanitarias (EPES)) in Andalusia during 2012, which served 8 393 159 people. Databases of the National Statistics Institute, Basic Spatial Data of Andalusia and System of Multiterritorial Information of Andalusia were used to retrieve spatial data and population characteristics. Geographic Information System software (QGIS and GeoDA) was used for analysis and linkage across databases. Spatial analyses of geographical location influence in hypoglycemic events were assessed using Moran’s I statistics, and linear regressions were used to determine their association with population characteristics.ResultsThe EPES attended 1 137 738 calls requesting medical assistance, with a mean hypoglycemia incidence of 95.0±61.6 cases per 100 000 inhabitants. There were significant differences in hypoglycemia incidence between basic healthcare zones attributable to their geographical location in the overall population (Moran’s I index 0.122, z-score 7.870, p=0.001), women (Moran’s I index 0.088, z-score 6.285, p=0.001), men (Moran’s I index 0.076, z-score 4.914, p=0.001) and aged >64 years (Moran’s I index 0.147, z-score 9.753, p=0.001). Hypoglycemia incidence was higher within unemployed individuals (β=0.003, p=0.001) and unemployed women (β=0.005, p=0.001), while lower within individuals aged <16 years (β=−0.004, p=0.040), higher academic level (secondary studies) (β=−0.003, p=0.004) and women with secondary studies (β=−0.005, p<0.001). In subjects aged >64 years, lower rate of hypoglycemia was associated with more single-person homes (β=−0.008, p=0.022) and sports facilities (β=−0.342, p=0.012).ConclusionsThis analysis supports the geographical distribution of hypoglycemia in the overall population, both genders and subjects aged >64 years, which was affected by societal factors such as unemployment, literacy/education, housing and sports facilities. These data can be useful to design specific prevention programs.

show abstract

Insulin detemir in the management of type 2 diabetes in non-Western countries: Safety and effectiveness data from the A1chieve observational study

Abstract: People with type 2 diabetes in poor glycaemic control starting treatment with insulin detemir reported significant improvements in glycaemic control with improved treatment tolerability, irrespective of prior treatment and geographical region, after 24 weeks.

Cited by 6 publications

References 26 publications

Comparison of the HAT study, the largest global hypoglycaemia study to date, with similar large real‐world studies

Comparison of the HAT study, the largest global hypoglycaemia study to date, with similar large real‐world studies

Análisis de costo-utilidad del uso de detemir en pacientes con diabetes tipo 2

Geographical clustering and socioeconomic factors associated with hypoglycemic events requiring emergency assistance in Andalusia (Spain)

Contact Info

Product

Resources

About